Observational study of the safety of buprenorphine+naloxone in pregnancy in a rural and remote population
| Autor: | Joseph Dooley, Jazmyn Balfour-Boehm, Craig Edwards, Naana Jumah, Kassandra Loewen, Len Kelly, Lianne Gerber Finn |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
Rural Population
medicine.medical_treatment Narcotic Antagonists 0302 clinical medicine Pregnancy Birth Weight 030212 general & internal medicine Ontario education.field_of_study 030219 obstetrics & reproductive medicine Obstetrics Naloxone Gestational age General Medicine Buprenorphine Treatment Outcome Apgar score Female Safety medicine.drug Adult medicine.medical_specialty Population Addiction 03 medical and health sciences medicine Humans Caesarean section education Retrospective Studies Indigenous health business.industry Research Infant Newborn Buprenorphine + naloxone medicine.disease Opioid-Related Disorders Pregnancy Complications Rural and remote Apgar Score Pregnant Women business Neonatal Abstinence Syndrome Methadone |
| Zdroj: | BMJ Open |
| ISSN: | 2044-6055 |
| Popis: | Objectives To describe the effect of in utero exposure to the buprenorphine+naloxone combination product in a rural and remote population. Setting A district hospital that services rural and remote, fly-in communities in Northwestern Ontario, Canada. Participants A retrospective cohort study was conducted of 855 mother infant dyads between 1 July 2013 and 30 June 2015. Cases included all women who had exposure to buprenorphine+naloxone during pregnancy (n=62). 2 control groups were identified; the first included women with no opioid exposure in pregnancy (n=618) and the second included women with opioid exposure other than buprenorphine+naloxone (n=159). Women were excluded if they had multiple pregnancy or if they were part of a methadone programme (n=16). The majority of women came from Indigenous communities. Outcomes The primary outcomes were birth weight, preterm delivery, congenital anomalies and stillbirth. Secondary neonatal outcomes included gestational age at delivery, Apgar scores at 1 and 5 min, NAS Score >7 and treatment for neonatal abstinence syndrome (NAS). Secondary maternal outcomes included the number of caesarean sections, postpartum haemorrhages, out of hospital deliveries and transfer of care to tertiary centres. Results No difference was found in the primary outcomes or in the Apgar score and caesarean section rate between in utero buprenorphine+naloxone exposure versus no opioid exposure in pregnancy. Compared to women taking other opioids, women taking buprenorphine+naloxone had higher birthweight babies (p=0.001) and less exposure to marijuana (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|